Abstract 1449P
Background
KN046 is a novel bispecific domain antibody, which blocks both PD-L1 and CTLA-4. KN046 combined with platinum-based chemotherapy as 1L treatment for NSCLC had shown promising efficacy and tolerability in the previous clinical trial. (2022 ESMO 1029P). Herein, we present the promising preliminary data of KN046 combination with axitinib as 1L treatment for NSCLC.
Methods
Eligible subjects with recurrent/metastatic NSCLC, treatment-naive and PD-L1 expression ≥1% will be enrolled and receive KN046 5mg/kg IV Q3W and axitinib 5mg orally bid. This study adopts a Simon’s optimal two-stage design. In the 1st stage, 17 subjects will be enrolled, and the 2nd stage enrollment will be discontinued if objective response (CR or PR) observed in less than 5 subjects. Otherwise, 37 subjects will be enrolled in the 2nd stage. The primary endpoint is ORR. The secondary endpoints include DoR, safety, PFS and OS.
Results
As of data cut-off date (Mar 17, 2023), 22 subjects were enrolled, the median age was 64.5y (min:37, max:73), 90.9% were male. ECOG score was 0 (4.5%) and 1 (95.5%). PD-L1 expression was ≥50% in 22.7% of the subjects. 15 subjects completed at least one tumor assessment. In the efficacy analysis set, the ORR was 66.7% (10/15). The median follow-up for DoR was 4.21 m (95% CI,1.22, NE). The 3-m DoR rate was 100% (95% CI, 100.00, 100.00). The median study follow-up was 2.83 m (95% CI,0.72, 5.12). The 6-m PFS rate was 76.6 % (95% CI, 41.16, 92.28), The mPFS and mOS was not reached. The incidence of TEAE was 81.8% (18/22), of which KN046-related TRAE was 63.6% (14/22). Majority was grade 1-2. The incidence of KN046-related CTCAE Grade ≥3 TRAE was 9.1% (2/22). The most frequent TRAE was AST increased 9.1% (2/22) and ALT increased 4.5% (1/22). The incidence of irAE was 13.6% (3/22), No CTCAE Grade ≥3 irAE was found. There was no KN046-related death.
Conclusions
KN046 combined with axitinib is well tolerated and has shown very promising efficacy and safety signal in 1L treatment for advanced NSCLC. The 2nd stage of enrollment is ongoing and a phase 3 RCT is planned to further confirm the clinical benefit of KN046 and axitinb combo as a viable chemo free option for the 1st line NSCLC patient.
Clinical trial identification
NCT05420220.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Jiangsu Alphamab Biopharmaceuticals Co.,Ltd., Suzhou, China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20
1402P - Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Presenter: Clarisse Audigier Valette
Session: Poster session 20
1403P - Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Presenter: Maria Lucia Reale
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Presenter: Friederike Althoff
Session: Poster session 20
1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
Presenter: J. Connor Wells
Session: Poster session 20
1407P - Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Presenter: Nicolas Girard
Session: Poster session 20
1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Presenter: Laura Masfarre Pinto
Session: Poster session 20
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
1410P - Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Presenter: Noemi Reguart Aransay
Session: Poster session 20